Exidavnemab phase 2a study expanded to include MSA patients
Go back to Exidavnemab phase 2a study expanded to include MSA patients| BARNES GROUP, Inc. (NYSE: B) | Delayed: 44.75 -1.01 (2.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $45.76 | 52 Week High | $44.27 | |||
| Open | $44.85 | 52 Week Low | $30.07 | |||
| Day High | $45.39 | P/E | 34.16 | |||
| Day Low | $44.47 | EPS | $1.31 | |||
| Volume | 6,199,162 | |||||
| BIOAMBER, Inc. (NASDAQ: BIOA) | Delayed: 9.59 +0.09 (0.95%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.50 | 52 Week High | $8.73 | |||
| Open | $9.39 | 52 Week Low | $2.86 | |||
| Day High | $9.76 | P/E | N/A | |||
| Day Low | $9.39 | EPS | $-3.82 | |||
| Volume | 314,854 | |||||
